Suppression of neointimal thickening by a newly developed HMG-CoA reductase inhibitor, BAYw6228, and its inhibitory effect on vascular smooth muscle cell growth

British Journal of Pharmacology

Volumn 120, Issue 6, 1997, Pages 1172-1178

  Igarashi, Masahiko ^a   Takeda, Yuki ^a   Mori, Seijiro ^b   Ishibashi, Naoko ^a   Komatsu, Eiichi ^a   Takahashi, Kentaro ^a   Fuse, Tsunekazu ^c   Yamamura, Mikako ^c   Kubo, Kazuki ^d   Sugiyama, Yasuo ^d   Saito, Yasushi ^b  

^a YAMAGATA UNIVERSITY   (Japan)

^b CHIBA UNIVERSITY   (Japan)

^c YAMAGATA UNIVERSITY HOSPITAL   (Japan)

^d TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

Author keywords

Balloon catheterization; BAYw6228; HMG CoA reductase inhibitor; Intimal thickening; Macrophage; Percutaneous transluminal coronary angioplasty (PTCA); Smooth muscle cell

Indexed keywords

ACTIN ANTIBODY; ALPHA ACTIN; CERIVASTATIN; CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PROTEIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AORTA; ARTERY INTIMA PROLIFERATION; ARTICLE; ATHEROGENESIS; BALLOON CATHETER; CELL GROWTH; CHOLESTEROL BLOOD LEVEL; COMMON CAROTID ARTERY; CONTROLLED STUDY; DRUG MECHANISM; EXTERNAL CAROTID ARTERY; FAMILIAL HYPERLIPEMIA; HUMAN; HUMAN CELL; MALE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONTENT; RABBIT; RAT; SUBCUTANEOUS DRUG ADMINISTRATION; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE;

ANIMALS; ARTERIOSCLEROSIS; BALLOON DILATATION; CAROTID ARTERIES; CELL DIVISION; CELLS, CULTURED; DNA; ENZYME INHIBITORS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; MUSCLE, SMOOTH, VASCULAR; PYRIDINES; RABBITS; RATS; RATS, SPRAGUE-DAWLEY; STEREOISOMERISM;

EID: 8044247790     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0701018     Document Type: Article

References (30)

1. ASADA, Y., TSUNEYOSHI, A., MARUTSUKA, K. & SUMIYOSHI, A. (1994). Suramin inhibits intimal thickening following intimal injury in the rabbit aorta in vivo. Cardiovasc. Res., 28, 1166-1169.
2. AUSTIN, G.E., RATLITT, N.B., HOLLMAN, J., TABEI, S. & PHILLIPS, D.F. (1985). Intimal proliferation of smooth muscle cells as an explanation for recurrent coronary artery stenosis after percutaneous transluminal coronary angioplasty. J. Am. Coll. Cardiol., 6, 369-375.
3. BOCAN, T.M.A., MAZUR, M.J., MUELLER, S.B., BROWN, E.Q., SLISKOVIC, D.R., O'BRIEN, P.M., CRESWELL, M.W., LEE, H., UHLENDORF, P.D., ROTH, B.D. & NEWTON, R.S. (1994). Anti-atherosclerotic activity of inhibitors of 3-hydroxy-3-methyl-glutaryl coenzyme A reductase in cholesterol-fed rabbits: a biochemical and morphological evaluation. Atherosclerosis, 111, 127-142.
4. CASSCELLS, W. (1992). Migration of smooth muscle and endothelial cells. Circulation, 86, 723-729.
5. CORSINI, A., MAZZOTTI, M., RAITERI, M., SOMA, M.R., GABBIANI, G., FUMAGALLI, R. & PAOLETTI, R. (1993). Relationship between mavalonate pathway and arterial myocyte proliferation: in vitro studies with inhibitors of HMG-CoA reductase. Atherosclerosis, 101, 117-125.
6. ENDO, A. (1992). The discovery and development of HMG-CoA reductase inhibitors. J. Lipid. Res., 33, 1569-1582.
7. FAXON, D.P. & CURRIER, J.W. (1995). Prevention of post-PTCA restenosis. Ann. New York Acad. Sci., 748, 419-427.
8. FISCHER-DZOGA, K., JONES, R.M., VESSELINOVITCH, D. & WISSLER, R.W. (1973). Ultra-structural and immunohistochemical studies of primary cultures of aortic medial cells. Exp. Mol. Pathol., 18, 162-176.
9. FRANKLIN, S.M. & FAXON, D.P. (1993). Pharmacologic prevention of restenosis after coronary angioplasty: review of randomized clinical trials. Coronary Artery Dis., 4, 232-242.
10. FUSTER, V., BADIMON, L., BADIMON, J.J. & CHESEBRO, J.H. (1992). The pathogenesis of coronary artery disease and acute coronary syndrome (1). N. Eng. J. Med., 326, 242-250.
11. GRUNDY, S.M. (1988). HMG-CoA reductase inhibitors for the treatment of hypercholesterolemia. N. Eng. J. Med., 319, 24-33.
12. HSU, S.M., RAINE, L. & FANGER, H. (1981). Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase technique: a comparison between ABC and unlabeled antibody (PAP) procedures. J. Histochem. Cytochem., 29, 577-580.
13. JACOBSSON, L.S., PERSSON, K., ABERG, G., ANDERSSON, R.G.G., KARLBERG, B.E. & OLSSON, A.G. (1994). Antiatherosclerotic effects of the angiotensin-converting enzyme inhibitors captopril and fosinopril in hypercholesterolemic minipigs. J. Cardiovasc. Pharmacol., 24, 670-677.
14. KANE, P., MALLOY, M.J., PORTS, T.A., PHILLIPS, N.R., DIEHL, J.C. & HARVEL, R.J. (1990). Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. J. Am. Med. Assoc., 264, 3007-3012.
15. KOBAYASHI, M, ISHIDA, F., TAKAHASHI, T., TAGUCHI, K., WATANABE, K., OHNUMA, I & KAMEI, T. (1989). Preventive effect of MK-733 (Simvastatin), an inhibitor of HMG-CoA reductase, on hypercholesterolemia and atherosclerosis induced by cholesterol feeding in rabbits. Jpn. J. Pharmacol., 49, 125-133.
16. LINDNER, V. & REIDY, M.A. (1991). Proliferation of smooth muscle cells after vascular injury is inhibited by an antibody against basic fibroblast growth factor. Proc. Natl. Acad. Sci. U.S.A., 88, 3739-3743.
17. LIU, M.W., ROUBIN, G.S. & KING, S.B. III (1994). Effect of angiographic and hemodynamic results of coronary balloon angioplasty on late angiographic outcome. Am. Heart J., 128, 1077-1083.
18. LOWRY, O.H., ROSEBROUGH, N.J., FARR, A.L. & RANDALL, R.J. (1950). Protein measurement with the folin phenol reagent. J. Biol. Chem., 193, 265-275.
19. MACK, W.J., SELZER, R.H., POGODA, J.M., LEE, P.L., SHIRCORE, A.M., AZEN, S.P. & BLANKENHORN, D.H. (1992). Comparison of computer- and human-derived coronary angiographic end-point measures for controlled therapy trials. Arterioscler. Thromb., 12, 348-356.
20. MOTOYAMA, Y., SEKI, J., KATOH, Y., NISHIO, M. & YOSHIDA, K. (1994). Effect of TFC-612, a 7-thia prostaglandin E1 derivative, on intimal thickening after endothelial injury with balloon catheter in rats. Atherosclerosis, 108, 159-165.
21. MEIER, R. (1988). Restenosis after coronary angioplasty: review of the literature. Eur. Heart J., 9, 1-6.
22. OTTO, J., ORDOVAS, J.M., SMITH, D., VAN DONGEN, D., NICOLOSI, R.J. & SCHAEFER, E.J. (1995). Lovastatin inhibits diet atherosclerosis in F1B Golden Syrian hamsters. Atherosclerosis, 114, 19-28.
23. POPMA, J.J., CALIFF, R.M. & TOPOL, E.J. (1991). Clinical trials of restenosis after coronary angioplasty. Circulation, 84, 1426-1436.
24. ROSS, R. (1986). The pathogenesis of atherosclerosis - An update. N. Eng. J. Med., 314, 488-500.
25. SOMA, M.R., DONETTI, E., PAROLINI C., MAZZINI, G., FERRARI, C., FUMAGALLI, R. & PAOLETTI, R. (1993). HMG CoA reductase inhibitors. In vitro effects on carotid intimal thickening in normocholesterolemic rabbits. Atheroscler. Thromb., 13, 571-578.
26. TIPPING, P.G. & HANCOCK, W.W. (1993). Production of tumor necrosis factor and interleukin-1 by macrophages from human atheromatous plaques. Am. J. Pathol., 142, 1721-1728.
27. WILENTZ, J.R., SANBORN, T.A., HAUDENSCHILD, C.C., VALERI, C.R., RYAN, T.J. & FAXON, D.P. (1991). Platelet accumulation in experimental angioplasty: time course and relation to vascular injury. Circulation, 75, 636-642.
28. WISSLER, R.W. (1991). Update on pathogenesis of atherosclerosis. Am. J. Med., 91, 3S-9S.
29. YUI, Y., KAWAI, C. & HOSODA, S. (1995). Pravastatin (mevalotin) restenosis trial after percutaneous transluminal coronary angioplasty. Cholesterol reduction rate determines the restenosis rate. Ann. New York Acad. Sci., 748, 208-216.
30. ZHU, B.Q., SIEVERS, R.E., SUN, Y.P., ISEMBERG, W.M. & PARMLEY, W.W. (1992). Effect of lovastatin on suppression and regression of atherosclerosis in lipid-fed rabbits. J. Cardiovasc. Pharmacol., 19, 246-255.